Zuellig Pharma Acquires Cialis Rights in Hong Kong, Macau, South Korea
This acquisition strengthens Zuellig Pharma's position in the Asian pharmaceutical market by expanding its portfolio of owned prescription products.
Acquisition of Cialis brand rights in three Asian markets.
This acquisition strengthens Zuellig Pharma's position in the Asian pharmaceutical market by expanding its portfolio of owned prescription products. It demonstrates a strategic move to gain greater control over key brands and enhance market access for important treatments like Cialis, which addresses common health concerns such as erectile dysfunction and benign prostatic hyperplasia. The expansion to 11 markets signifies a significant step in their regional growth strategy and commitment to making healthcare more accessible.
The acquisition specifically targets markets in East Asia (Hong Kong, Macau, South Korea), indicating a focused expansion strategy within the region. This move is significant given the growing demand for pharmaceutical products and healthcare solutions across Asia.
Zuellig Pharma has acquired all rights to Cialis (Tadalafil) from Eli Lilly and Company in Hong Kong, Macau, and South Korea. This expansion increases Zuellig Pharma's ownership of the brand to 11 markets across Asia. The move aligns with the company's strategy to build a strong portfolio of owned prescription healthcare products, aiming to broaden access to treatments for erectile dysfunction and benign prostatic hyperplasia.
Where this signal fits in the broader landscape.
https://www.linkedin.com/posts/zuellig-pharma_we-are-pleased-to-share-that-zuellig-pharma-activity-7437700556430675968-J9uW
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In